Results 41 to 50 of about 5,803 (182)
Prenatal testing and postpartum treatment for hepatitis C virus among women with opioid use disorder
Pregnancy, Volume 2, Issue 5, September 2026.Abstract Introduction In the past decade, hepatitis C virus (HCV) infections among pregnant women increased dramatically in the United States, rising in parallel with the opioid crisis and increasing the number of children at risk for HCV. People with HCV infection that remains untreated are also at increased risk of cirrhosis, liver cancer, and death.
Lucas Gosdin +19 more
wiley +1 more source
Journal of Virus Eradication, 2020 Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber +3 more
doaj +1 more source
Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.ABSTRACT The burden of hepatitis C virus (HCV) infection often falls disproportionately on migrant populations within high‐income countries. Differences in health literacy, language, comorbidities, and HCV genotype may influence HCV natural history. 3537 persons including 652 migrants treated for HCV infection with direct‐acting antiviral (DAA) (2016 ...
Belaynew W. Taye +17 more
wiley +1 more source
The SVR12 rates of patients treated with ledipasvir and sofosbuvir.
, 2018 The SVR12 rates of patients treated with ledipasvir and sofosbuvir.
Takeshi Kure (5328974) +16 more
core +1 more source
Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery
Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju +3 more
wiley +1 more source
, 2017 Chronic hepatitis C virus (HCV) infection is one of the most common etiologies of liver-related mortality throughout the world. Sofosbuvir and ledipasvir are inhobits HCV NS5B and HCV NS5A polymerase respectively.
S. Naazneen*, A. Sridevi
core +1 more source
Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents
Anales de Pediatría (English Edition), 2019 Introduction: The aim of this study was to assess the safety and efficacy of ledipasvir/sofosbuvir combination in chronic Hepatitis C Virus (HCV) genotype 1 and 4 infection in paediatric patients.
Jesús Quintero +7 more
doaj +1 more source
Cancer Medicine, Volume 15, Issue 6, June 2026.ABSTRACT Aim We examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR). Methods Clinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group ...
Shinji Itoh +22 more
wiley +1 more source
Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C
Anales de Pediatría, 2019 Resumen: Introducción: El objetivo del estudio fue evaluar la seguridad y la eficacia de la combinación de ledipasvir/sofosbuvir en la infección crónica por el genotipo 1 y 4 del virus de la hepatitis C (VHC) en pacientes pediátricos.
Jesús Quintero +7 more
doaj +1 more source
PLoS ONE, 2023 BackgroundInsurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs and medication adherence.
William Bruce Wong +3 more
doaj +1 more source